DK2009000T3 - Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme - Google Patents

Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme

Info

Publication number: DK2009000T3
Authority: DK; Denmark
Prior art keywords: receptor inverse; compound; neurodegenerative diseases; therapeutics; efficacy
Prior art date: 2003-01-16

Application number

DK08015449.5T

Other languages

English (en)

Inventor

Robert E Davis

Mark R Brann

Norman Nash

Carl-Magnus A Andersson

Allan K Uldam

M David Weiner

Original Assignee

Acadia Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-16

Filing date

2004-01-15

Publication date

2011-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2009000(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-15 Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc

2011-09-05 Application granted granted Critical

2011-09-05 Publication of DK2009000T3 publication Critical patent/DK2009000T3/da

Links

239000003814 drug Substances 0.000 title abstract 2
230000004770 neurodegeneration Effects 0.000 title abstract 2
208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
239000002469 receptor inverse agonist Substances 0.000 title abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
229940076279 serotonin Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000012661 Dyskinesia Diseases 0.000 abstract 2
208000028017 Psychotic disease Diseases 0.000 abstract 2
230000000561 anti-psychotic effect Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 abstract 1
101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
230000008484 agonism Effects 0.000 abstract 1
239000000002 anti-dyskinesia agent Substances 0.000 abstract 1
230000003374 anti-dyskinetic effect Effects 0.000 abstract 1
230000006399 behavior Effects 0.000 abstract 1
230000003542 behavioural effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000003137 locomotive effect Effects 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
238000011809 primate model Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DK08015449.5T 2003-01-16 2004-01-15 Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme DK2009000T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US44140603P	2003-01-16	2003-01-16
US47934603P	2003-06-17	2003-06-17
EP04702584A EP1587789B1 (en)	2003-01-16	2004-01-15	Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases

Publications (1)

Publication Number	Publication Date
DK2009000T3 true DK2009000T3 (da)	2011-09-05

Family

ID=32776052

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08015449.5T DK2009000T3 (da)	2003-01-16	2004-01-15	Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
DK04702584T DK1587789T3 (da)	2003-01-16	2004-01-15	Selektiv serotomin - 2A/2C - receptor - inverse - agonister som terapeutiske midler til neurodegenerative sygdomme

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK04702584T DK1587789T3 (da)	2003-01-16	2004-01-15	Selektiv serotomin - 2A/2C - receptor - inverse - agonister som terapeutiske midler til neurodegenerative sygdomme

Country Status (21)

Country	Link
US (17)	US7601740B2 (da)
EP (2)	EP1587789B1 (da)
JP (2)	JP5184777B2 (da)
KR (1)	KR101095939B1 (da)
CN (3)	CN1816524B (da)
AT (2)	ATE407117T1 (da)
AU (1)	AU2004206886B2 (da)
BR (1)	BRPI0406591B8 (da)
CA (1)	CA2512639C (da)
CY (1)	CY1108642T1 (da)
DE (1)	DE602004016288D1 (da)
DK (2)	DK2009000T3 (da)
ES (2)	ES2367135T3 (da)
MX (1)	MXPA05007568A (da)
NZ (1)	NZ541146A (da)
PT (1)	PT1587789E (da)
RU (2)	RU2332401C2 (da)
SG (1)	SG170617A1 (da)
SI (2)	SI1587789T1 (da)
WO (1)	WO2004064738A2 (da)
ZA (1)	ZA200505680B (da)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2278729T3 (es) *	2000-03-06	2007-08-16	Acadia Pharmaceuticals Inc.	Compuestos azaciclicos para usar en el tratamiento de enfermedades relacionadas con la serotonina.
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de)	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
MXPA04006280A (es) *	2001-12-28	2004-09-27	Acadia Pharm Inc	Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
US7253186B2 (en) *	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en)	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
EP1562937A2 (en) *	2002-06-24	2005-08-17	Acadia Pharmaceuticals Inc.	N-substituted piperidine derivatives as serotonin receptor agents
MY139563A (en) *	2002-09-04	2009-10-30	Bristol Myers Squibb Co	Heterocyclic aromatic compounds useful as growth hormone secretagogues
DK2009000T3 (da) *	2003-01-16	2011-09-05	Acadia Pharm Inc	Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
CN1741803A (zh) *	2003-01-23	2006-03-01	阿卡蒂亚药品公司	N－脱甲基氯氮平在治疗人神经精神疾病中的用途
US20040253274A1 (en) *	2003-06-11	2004-12-16	Allergan, Inc.	Use of a clostridial toxin to reduce appetite
NZ527142A (en)	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
US20050203130A1 (en) *	2003-12-02	2005-09-15	Erik Buntinx	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) *	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) *	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) *	2003-12-02	2005-06-16	B&B Beheer Nv	Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US20050119249A1 (en) *	2003-12-02	2005-06-02	Erik Buntinx	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
SG133606A1 (en)	2003-12-22	2007-07-30	Acadia Pharm Inc	Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050261278A1 (en) *	2004-05-21	2005-11-24	Weiner David M	Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) *	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) *	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CA2580129A1 (en) *	2004-09-27	2006-04-06	Acadia Pharmaceuticals Inc.	Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
KR20060030175A (ko) *	2004-10-05	2006-04-10	경북대학교 산학협력단	무정위성 운동 치료용 약학조성물
TW200806321A (en) *	2006-03-24	2008-02-01	Wyeth Corp	New therapeutic combinations for the treatment or prevention of psychotic disorders
US20080051429A1 (en) *	2006-04-19	2008-02-28	Van Kammen Daniel	Use of 4-amino-piperidines for treating sleep disorders
WO2007133802A2 (en) *	2006-05-15	2007-11-22	Acadia Pharmaceuticals Inc.	Pharmaceutical formulations of pimavanserin
US20080039535A1 (en) *	2006-08-14	2008-02-14	Wyeth	Methods of identifying agents for treating neurological disorders
US20080254118A1 (en) *	2007-04-11	2008-10-16	Hans-Werner Wernersbach	Process for preparing pramipexole dihydrochloride tablets
US20100151459A1 (en) *	2007-01-26	2010-06-17	Jun Soo Kwon	Marker for detecting the proposed efficacy of treatment
CA2681506C (en) *	2007-03-19	2016-05-24	Perry Peters	Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
US20080254117A1 (en) *	2007-04-10	2008-10-16	Noel Cotton	Process for preparing pramipexole dihydrochloride tablets
JP2010525018A (ja) *	2007-04-24	2010-07-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
US20110111014A1 (en) *	2007-06-26	2011-05-12	Parkinson's Institute	Methods and compositions for treatment of neurological disorders
JP2010540454A (ja) *	2007-09-21	2010-12-24	アカディアファーマシューティカルズ，インコーポレーテッド	ピマバンセリンと他の薬剤との併用投与
CA2700332A1 (en) *	2007-09-21	2009-03-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
WO2009123714A2 (en)	2008-04-02	2009-10-08	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CN104739829B (zh)	2008-10-28	2018-11-06	艾尼纳制药公司	用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
US9737531B2 (en)	2012-07-12	2017-08-22	Glytech, Llc	Composition and method for treatment of depression and psychosis in humans
WO2013155504A1 (en)	2012-04-14	2013-10-17	Intra-Cellular Therapies, Inc.	Novel methods
WO2014085362A1 (en)	2012-11-27	2014-06-05	Acadia Pharmaceuticals Inc.	Methods for the treatment of parkinson's disease psychosis using pimavanserin
IL305990B2 (en)	2013-12-03	2025-12-01	Intra Cellular Therapies Inc	Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
TWI703130B (zh) *	2014-03-07	2020-09-01	瑞士商赫爾辛保健股份有限公司	對位取代的不對稱脲及其醫療用途
CN104961671B (zh) *	2014-09-05	2018-01-02	苏州晶云药物科技有限公司	N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法
KR20210095734A (ko) *	2015-01-28	2021-08-02	주식회사 제네리스코리아	신경정신계 장애의 치료를 위한 조성물 및 방법
WO2016141003A1 (en)	2015-03-02	2016-09-09	Teva Pharmaceutical Industries Ltd.	Processes and intermediates for the preparation of pimavanserin
WO2017011767A2 (en) *	2015-07-15	2017-01-19	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
ES2890492T3 (es) *	2015-07-20	2022-01-20	Acadia Pharm Inc	Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
CZ2015601A3 (cs)	2015-09-02	2017-03-15	Zentiva, K.S.	Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CZ2015688A3 (cs)	2015-10-02	2017-04-12	Zentiva, K.S.	Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů
CN105523993A (zh) *	2015-12-28	2016-04-27	重庆两江药物研发中心有限公司	N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用
CN108884026B (zh)	2016-03-22	2021-05-25	赫尔森保健股份公司	苯磺酰基不对称尿素及其医学用途
WO2017165635A1 (en)	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en)	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
EP3436010B1 (en)	2016-03-29	2021-03-10	Acadia Pharmaceuticals Inc.	5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
CN107343887A (zh) *	2016-05-06	2017-11-14	常州爱诺新睿医药技术有限公司	一种无定型半酒石酸匹莫范色林与药用辅料的固体分散体及其制备方法
CN106179449B (zh) *	2016-07-18	2018-11-13	南京工业大学	一种碳氮材料负载的钴催化剂及合成哌马色林中间体的方法
BR112019004935A2 (pt)	2016-09-13	2019-06-04	Allergan, Inc.	composições de toxina clostridial não proteíca estabilizada
WO2018064465A1 (en)	2016-09-29	2018-04-05	The Regents Of The University Of California	Compounds for increasing neural plasticity
US11331316B2 (en)	2016-10-12	2022-05-17	Intra-Cellular Therapies, Inc.	Amorphous solid dispersions
EP3558311A1 (en) *	2016-12-20	2019-10-30	Acadia Pharmaceuticals Inc.	Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
IL268970B2 (en)	2017-03-24	2023-12-01	Intra Cellular Therapies Inc	Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
EP3615028A1 (en)	2017-04-28	2020-03-04	Acadia Pharmaceuticals Inc.	Pimavanserin for treating impulse control disorder
RU2019143572A (ru)	2017-05-25	2021-06-25	Глитек Ллс.	Композиции для лечения посттравматического стрессового расстройства
AU2018284335A1 (en)	2017-06-12	2020-01-30	Glytech Llc.	Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists
CN109111385B (zh) *	2017-06-23	2023-06-30	上海翰森生物医药科技有限公司	5-ht2a受体抑制剂及其制备方法和应用
MX2020001757A (es)	2017-08-21	2020-09-07	Acadia Pharm Inc	Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EP3672960A2 (en)	2017-08-21	2020-07-01	Acadia Pharmaceuticals Inc.	Compounds, salts thereof and their use for the treatment of diseases
EP3675827A1 (en)	2017-08-30	2020-07-08	Acadia Pharmaceuticals Inc.	Formulations of pimavanserin
CN109568278A (zh) *	2017-09-28	2019-04-05	北京万全德众医药生物技术有限公司	匹莫范色林片剂及其制备方法
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3709999B1 (en)	2017-11-13	2024-02-14	Texas Tech University System	Compositions and methods for treating cancer
KR102036909B1 (ko) *	2017-11-28	2019-10-25	한국과학기술원	신규 디스토니아 치료용 약학적 조성물
WO2019178484A1 (en)	2018-03-16	2019-09-19	Intra-Cellular Therapies, Inc.	Novel methods
IT201800003736A1 (it)	2018-03-19	2019-09-19	Lundbeck Pharmaceuticals Italy S P A	Processo per la produzione di Pimavanserin
US20190359985A1 (en) *	2018-05-22	2019-11-28	John Lawrence Mee	Adjustable method for sustainable human cognitive enhancement
CN108947891B (zh)	2018-07-26	2021-02-09	丽珠集团新北江制药股份有限公司	利用三光气安全制备匹莫范色林及其酒石酸盐的方法
EP3843729A4 (en)	2018-08-29	2022-06-01	Intra-Cellular Therapies, Inc.	NOVEL COMPOSITIONS AND PROCESSES
CN112584837A (zh)	2018-08-31	2021-03-30	细胞内治疗公司	新方法
CA3108558A1 (en)	2018-08-31	2020-03-05	Intra-Cellular Therapies, Inc.	Novel methods
IT201800009690A1 (it)	2018-10-23	2020-04-23	Lundbeck Pharmaceuticals Italy Spa	Processo per la produzione di pimavanserina
CN113784962B (zh)	2019-02-27	2025-04-25	加利福尼亚大学董事会	用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
AU2020228289B2 (en)	2019-02-27	2026-02-05	The Regents Of The University Of California	N-substituted indoles and other heterocycles for treating brain disorders
KR20220009954A (ko)	2019-04-17	2022-01-25	컴퍼스 패쓰파인더 리미티드	신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP7673040B2 (ja)	2019-07-07	2025-05-08	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規方法
WO2021016369A1 (en)	2019-07-22	2021-01-28	Acadia Pharmaceuticals Inc.	Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20220323429A1 (en) *	2019-08-15	2022-10-13	Acadia Pharmaceuticals Inc.	Pimavanserin for treating neurodegenerative diseases
KR102227268B1 (ko) *	2019-10-07	2021-03-12	한국과학기술원	디스토니아 치료 후보 약물의 신규 스크리닝 방법
WO2021147818A1 (zh) *	2020-01-21	2021-07-29	瀚远医药有限公司	5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN113214141B (zh) *	2020-01-21	2022-04-08	瀚远医药有限公司	5ht2a受体拮抗剂及其制备和应用
CN115677723B (zh) *	2020-01-21	2024-06-04	瀚远医药有限公司	5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
US12527775B2 (en)	2020-03-26	2026-01-20	Shionogi & Co., Ltd.	Heteroaromatic derivatives having serotonin receptor binding activity
WO2021206741A1 (en) *	2020-04-09	2021-10-14	Delahoussaye Kevin	Modulating neurotransmitter concentration
CN114728933B (zh) *	2020-07-22	2023-06-16	山东绿叶制药有限公司	5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
US11071739B1 (en)	2020-09-29	2021-07-27	Genus Lifesciences Inc.	Oral liquid compositions including chlorpromazine
WO2022098106A1 (ko) *	2020-11-04	2022-05-12	주식회사 오에이티씨	클로르프로마진을 포함하는 신경 염증성 질환의 예방 또는 치료용 조성물
CN113292484B (zh) *	2021-06-04	2022-11-15	沈阳药科大学	3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用
TW202333668A (zh)	2021-12-15	2023-09-01	美商德利克斯醫療公司	經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods
EP4570793A1 (en)	2022-08-03	2025-06-18	Luye Innomind Pharma Shijiazhuang Co., Ltd.	5-ht2a receptor inverse agonist, and preparation method therefor and use thereof
JP7406285B1 (ja)	2023-03-09	2023-12-27	国立大学法人島根大学	ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物
WO2025162237A1 (zh) *	2024-02-02	2025-08-07	绿叶嘉奥制药石家庄有限公司	一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA684843A (en)		1964-04-21	P. Roberts Cecil	Cap aligning mechanism
US165225A (en) *		1875-07-06		Improvement in hubs
BE794333A (fr)	1972-01-20	1973-07-19	Wyeth John & Brother Ltd	Composes heterocycliques azotes therapeutiques
GB1507462A (en)	1974-03-21	1978-04-12	Gallardo Antonio Sa	N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en)	1974-07-04	1976-09-28	Sandoz Ltd.	Treatment of dyskinesias
JPS5152176A (da)	1974-10-12	1976-05-08	Yoshitomi Pharmaceutical
JPS528517A (en)	1975-07-09	1977-01-22	Toyo Autom Kk	Fluid line automatic closing system at an earthquake
GB1586468A (en)	1976-10-29	1981-03-18	Anphar Sa	Piperidine derivatives
CA1140119A (en)	1978-04-03	1983-01-25	Joseph Torremans	N-heterocyclyl-4-piperidinamines
US4255432A (en)	1979-09-06	1981-03-10	Syntex (U.S.A.) Inc.	8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en)	1981-03-23	1982-06-01	Syntex (U.S.A.) Inc.	9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353901A (en)	1981-10-19	1982-10-12	Syntex (U.S.A.) Inc.	9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en)	1981-10-19	1982-10-12	Syntex (U.S.A.) Inc.	9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
GB8527052D0 (en)	1985-11-02	1985-12-04	Beecham Group Plc	Compounds
GB8621892D0 (en)	1986-09-11	1986-10-15	Lundbeck & Co As H	Organic compound
FR2642069B1 (fr)	1989-01-20	1991-04-12	Rhone Poulenc Sante	Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en)	1990-05-18	1993-05-25	Adir Et Compagnie	Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en)	1990-10-03	1993-06-01	American Home Products Corporation	N-substituted aminoquinolines as analgesic agents
IT1252227B (it)	1991-12-17	1995-06-05	Ciba Geigy Spa	Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
JPH05208517A (ja)	1992-01-31	1993-08-20	Nec Corp	印字制御回路
US5595872A (en)	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en)	1993-05-21	1994-11-22	Noriyoshi Sueda	Urea derivatives and their use as acat inhibitors
EP0700385A1 (en)	1993-05-26	1996-03-13	Smithkline Beecham Laboratoires Pharmaceutiques	Novel compounds
IL110298A (en)	1993-07-13	1999-04-11	Brann Mark Robert	Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de)	1994-02-10	1995-08-17	Merck Patent Gmbh	4-Amino-1-piperidylbenzoylguanidine
US5795894A (en)	1995-05-02	1998-08-18	Schering Corporation	Piperazino derivatives as neurokinn antagonists
BR9610277A (pt)	1995-08-31	1999-07-06	Schering Corp	Derivados de piperazino como antagonistas de neurowuinina
DE69633245T2 (de)	1995-09-29	2005-09-08	Eli Lilly And Co., Indianapolis	Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
PT871440E (pt) *	1995-12-07	2006-07-31	Daniel C Javitt	Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
JP2001519766A (ja)	1996-04-03	2001-10-23	メルクエンドカンパニーインコーポレーテッド	ファルネシルタンパク質トランスフェラーゼの阻害剤
DE69729583T2 (de)	1996-04-17	2005-06-09	Bristol-Myers Squibb Pharma Co.	N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
US5869488A (en)	1996-05-01	1999-02-09	Schering Corporation	Piperazino derivatives as neurokinin antagonists
AU4078997A (en) *	1996-08-22	1998-03-06	New York University	Cholinesterase inhibitors for treatment of parkinson's disease
US5877173A (en) *	1996-08-28	1999-03-02	Washington University	Preventing neuronal degeneration in Alzheimer's disease
DE59711622D1 (de)	1996-09-10	2004-06-17	Boehringer Ingelheim Pharma	Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19643331A1 (de)	1996-10-21	1998-04-23	Thomae Gmbh Dr K	1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9604786D0 (sv) *	1996-12-20	1996-12-20	Astra Pharma Inc	New compounds
US6057338A (en)	1997-04-04	2000-05-02	Merck & Co., Inc.	Somatostatin agonists
WO1998050534A1 (en)	1997-05-08	1998-11-12	Smithkline Beecham Corporation	Protease inhibitors
GB9718833D0 (en)	1997-09-04	1997-11-12	Merck Sharp & Dohme	Therapeutic agents
MXPA00010060A (es)	1998-04-14	2004-04-23	Arena Pharm Inc	Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos.
US6140509A (en)	1998-06-26	2000-10-31	Arena Pharmaceuticals, Inc.	Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en)	1998-07-24	1998-09-23	Merck Sharp & Dohme	Therapeutic agents
US6358698B1 (en)	1998-10-07	2002-03-19	Acadia Pharmacueticals Inc.	Methods of identifying inverse agonists of the serotonin 2A receptor
AU762345B2 (en)	1998-10-16	2003-06-26	Asubio Pharma Co., Ltd.	Aminophenoxyacetic acid derivatives as neuroprotectants
US6150393A (en)	1998-12-18	2000-11-21	Arena Pharmaceuticals, Inc.	Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (en)	1998-12-23	2000-06-28	Pfizer Inc.	Aminoazacycloalkanes as CCR5 modulators
US6725038B1 (en)	1999-01-26	2004-04-20	Nokia Corporation	Method and apparatus for speeding up AAL2 connection setup during handover in advanced cellular networks
WO2000056335A1 (en)	1999-03-24	2000-09-28	The Regents Of The University Of California	Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
US6399619B1 (en)	1999-04-06	2002-06-04	Merck & Co., Inc.	Pyrrolidine modulators of chemokine receptor activity
WO2000069810A1 (en)	1999-05-17	2000-11-23	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
US20050148018A1 (en)	1999-10-07	2005-07-07	David Weiner	Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr)	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) *	1999-12-28	2006-04-04	U & I Pharmaceuticals, Ltd.	Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6834122B2 (en)	2000-01-22	2004-12-21	Kairos Scientific, Inc.	Visualization and processing of multidimensional data using prefiltering and sorting criteria
ES2278729T3 (es)	2000-03-06	2007-08-16	Acadia Pharmaceuticals Inc.	Compuestos azaciclicos para usar en el tratamiento de enfermedades relacionadas con la serotonina.
GB0011838D0 (en)	2000-05-17	2000-07-05	Astrazeneca Ab	Chemical compounds
DE60141752D1 (de) *	2000-06-30	2010-05-20	Innogenetics Nv	Differentielle diagnose von neurologischen krankheiten
IL154363A0 (en)	2000-09-25	2003-09-17	Actelion Pharmaceuticals Ltd	Substituted amino-aza-cycloalkanes useful against malaria
WO2002076464A1 (en)	2001-03-22	2002-10-03	Arena Pharmaceuticals, Inc.	Anti-psychosis combination
GB0108099D0 (en)	2001-03-30	2001-05-23	Hoffmann La Roche	Aminopiperidine derivatives
MXPA04006280A (es)	2001-12-28	2004-09-27	Acadia Pharm Inc	Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
WO2003062206A2 (en)	2002-01-23	2003-07-31	Arena Pharmaceuticals, Inc.	Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
UY27668A1 (es)	2002-02-20	2003-10-31	Pfizer Prod Inc	Composición de ziprasidona y controles sintéticos
GB0208279D0 (en)	2002-04-10	2002-05-22	Glaxo Group Ltd	Novel compounds
US7538222B2 (en)	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en)	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
EP1562937A2 (en)	2002-06-24	2005-08-17	Acadia Pharmaceuticals Inc.	N-substituted piperidine derivatives as serotonin receptor agents
WO2004039322A2 (en)	2002-10-29	2004-05-13	Miicro, Inc.	Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
DK2009000T3 (da)	2003-01-16	2011-09-05	Acadia Pharm Inc	Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
CN1741803A (zh)	2003-01-23	2006-03-01	阿卡蒂亚药品公司	N－脱甲基氯氮平在治疗人神经精神疾病中的用途
CA2547639A1 (en)	2003-12-02	2005-06-16	B&B Beheer Nv	Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
SG133606A1 (en)	2003-12-22	2007-07-30	Acadia Pharm Inc	Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050261278A1 (en)	2004-05-21	2005-11-24	Weiner David M	Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en)	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
CA2580129A1 (en)	2004-09-27	2006-04-06	Acadia Pharmaceuticals Inc.	Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP5208517B2 (ja)	2005-01-10	2013-06-12	タヘリラドュカエルエルシー	血管移植物およびその製造方法
US7803951B2 (en)	2005-03-30	2010-09-28	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8572080B2 (en)	2010-06-04	2013-10-29	Salesforce.Com, Inc.	Methods and systems for analyzing a network feed in a multi-tenant database system environment
US9737531B2 (en)	2012-07-12	2017-08-22	Glytech, Llc	Composition and method for treatment of depression and psychosis in humans
WO2014085362A1 (en) *	2012-11-27	2014-06-05	Acadia Pharmaceuticals Inc.	Methods for the treatment of parkinson's disease psychosis using pimavanserin
US10953000B2 (en) *	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) *	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
EP3675827A1 (en) *	2017-08-30	2020-07-08	Acadia Pharmaceuticals Inc.	Formulations of pimavanserin

2004
- 2004-01-15 DK DK08015449.5T patent/DK2009000T3/da active
- 2004-01-15 ES ES08015449T patent/ES2367135T3/es not_active Expired - Lifetime
- 2004-01-15 KR KR1020057013195A patent/KR101095939B1/ko not_active Expired - Lifetime
- 2004-01-15 DK DK04702584T patent/DK1587789T3/da active
- 2004-01-15 AU AU2004206886A patent/AU2004206886B2/en not_active Expired
- 2004-01-15 ES ES04702584T patent/ES2314362T3/es not_active Expired - Lifetime
- 2004-01-15 NZ NZ541146A patent/NZ541146A/en not_active IP Right Cessation
- 2004-01-15 CN CN2004800044790A patent/CN1816524B/zh not_active Expired - Lifetime
- 2004-01-15 WO PCT/US2004/001234 patent/WO2004064738A2/en not_active Ceased
- 2004-01-15 CN CN2010105460287A patent/CN102028949A/zh active Pending
- 2004-01-15 PT PT04702584T patent/PT1587789E/pt unknown
- 2004-01-15 SG SG200705308-5A patent/SG170617A1/en unknown
- 2004-01-15 RU RU2005125918/04A patent/RU2332401C2/ru active
- 2004-01-15 AT AT04702584T patent/ATE407117T1/de active
- 2004-01-15 EP EP04702584A patent/EP1587789B1/en not_active Expired - Lifetime
- 2004-01-15 AT AT08015449T patent/ATE512136T1/de not_active IP Right Cessation
- 2004-01-15 CN CN200910225582.2A patent/CN101780080B/zh not_active Expired - Lifetime
- 2004-01-15 CA CA2512639A patent/CA2512639C/en not_active Expired - Lifetime
- 2004-01-15 EP EP08015449A patent/EP2009000B1/en not_active Expired - Lifetime
- 2004-01-15 MX MXPA05007568A patent/MXPA05007568A/es active IP Right Grant
- 2004-01-15 JP JP2006501009A patent/JP5184777B2/ja not_active Expired - Lifetime
- 2004-01-15 US US10/759,561 patent/US7601740B2/en active Active
- 2004-01-15 SI SI200430956T patent/SI1587789T1/sl unknown
- 2004-01-15 BR BRPI0406591A patent/BRPI0406591B8/pt not_active IP Right Cessation
- 2004-01-15 SI SI200431728T patent/SI2009000T1/sl unknown
- 2004-01-15 DE DE602004016288T patent/DE602004016288D1/de not_active Expired - Lifetime
2005
- 2005-07-14 ZA ZA200505680A patent/ZA200505680B/en unknown
2006
- 2006-05-03 US US11/416,855 patent/US7659285B2/en active Active
- 2006-05-03 US US11/416,527 patent/US7732462B2/en active Active
- 2006-05-03 US US11/416,594 patent/US7713995B2/en not_active Expired - Lifetime
2008
- 2008-04-16 RU RU2008115009/04A patent/RU2465267C2/ru active
- 2008-12-03 CY CY20081101402T patent/CY1108642T1/el unknown
2010
- 2010-03-10 JP JP2010053450A patent/JP2010174026A/ja active Pending
- 2010-04-13 US US12/759,664 patent/US8008323B2/en not_active Expired - Lifetime
- 2010-04-13 US US12/759,662 patent/US7994193B2/en not_active Expired - Lifetime
2011
- 2011-06-27 US US13/169,893 patent/US8227487B2/en not_active Expired - Fee Related
2012
- 2012-06-29 US US13/539,011 patent/US8377959B2/en not_active Expired - Fee Related
2013
- 2013-01-25 US US13/750,778 patent/US8618130B2/en not_active Expired - Fee Related
- 2013-11-21 US US14/086,838 patent/US8921393B2/en not_active Expired - Lifetime
2014
- 2014-11-10 US US14/537,793 patent/US9211289B2/en not_active Expired - Lifetime
2015
- 2015-11-06 US US14/935,246 patent/US9566271B2/en not_active Expired - Fee Related
2017
- 2017-01-03 US US15/397,582 patent/US10028944B2/en not_active Expired - Lifetime
2018
- 2018-06-26 US US16/019,485 patent/US10525046B2/en not_active Expired - Lifetime
2019
- 2019-11-18 US US16/687,467 patent/US20200323836A1/en not_active Abandoned
2021
- 2021-01-29 US US17/162,476 patent/US20240091212A1/en not_active Abandoned
- 2021-09-14 US US17/474,816 patent/US20220241265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7601740B2 (en)	2009-10-13
ES2367135T3 (es)	2011-10-28
WO2004064738A3 (en)	2004-11-25
US7732462B2 (en)	2010-06-08
US20100227886A1 (en)	2010-09-09
NZ541146A (en)	2009-04-30
JP2006516284A (ja)	2006-06-29
AU2004206886B2 (en)	2010-09-02
ES2314362T3 (es)	2009-03-16
AU2004206886A1 (en)	2004-08-05
ATE407117T1 (de)	2008-09-15
US20190030015A1 (en)	2019-01-31
ATE512136T1 (de)	2011-06-15
US7659285B2 (en)	2010-02-09
SI1587789T1 (sl)	2009-02-28
US8618130B2 (en)	2013-12-31
ZA200505680B (en)	2006-04-26
US20150202194A1 (en)	2015-07-23
WO2004064738A2 (en)	2004-08-05
US20040213816A1 (en)	2004-10-28
US20220241265A1 (en)	2022-08-04
US20100227885A1 (en)	2010-09-09
US20120277221A1 (en)	2012-11-01
US20240091212A1 (en)	2024-03-21
HK1126776A1 (en)	2009-09-11
RU2332401C2 (ru)	2008-08-27
CN101780080B (zh)	2014-06-04
CY1108642T1 (el)	2014-04-09
EP2009000B1 (en)	2011-06-08
BRPI0406591A (pt)	2005-12-20
KR101095939B1 (ko)	2011-12-19
US20060199842A1 (en)	2006-09-07
US20140140982A1 (en)	2014-05-22
RU2008115009A (ru)	2009-10-27
CN102028949A (zh)	2011-04-27
BRPI0406591B8 (pt)	2021-05-25
US20160250200A1 (en)	2016-09-01
BRPI0406591B1 (pt)	2018-12-18
US8227487B2 (en)	2012-07-24
US20060264466A1 (en)	2006-11-23
SG170617A1 (en)	2011-05-30
RU2005125918A (ru)	2006-02-10
US10525046B2 (en)	2020-01-07
US9211289B2 (en)	2015-12-15
CN101780080A (zh)	2010-07-21
CN1816524A (zh)	2006-08-09
HK1083759A1 (en)	2006-07-14
US8008323B2 (en)	2011-08-30
US20170209424A1 (en)	2017-07-27
CA2512639C (en)	2012-10-30
US9566271B2 (en)	2017-02-14
US20060264465A1 (en)	2006-11-23
US20110257229A1 (en)	2011-10-20
RU2465267C2 (ru)	2012-10-27
US7713995B2 (en)	2010-05-11
DK1587789T3 (da)	2009-01-05
PT1587789E (pt)	2008-12-16
US7994193B2 (en)	2011-08-09
US8921393B2 (en)	2014-12-30
JP2010174026A (ja)	2010-08-12
JP5184777B2 (ja)	2013-04-17
US20200323836A1 (en)	2020-10-15
CA2512639A1 (en)	2004-08-05
EP1587789A2 (en)	2005-10-26
SI2009000T1 (sl)	2011-09-30
DE602004016288D1 (de)	2008-10-16
MXPA05007568A (es)	2005-09-21
KR20050094857A (ko)	2005-09-28
US8377959B2 (en)	2013-02-19
EP2009000A1 (en)	2008-12-31
US20130137727A1 (en)	2013-05-30
US10028944B2 (en)	2018-07-24
EP1587789B1 (en)	2008-09-03
CN1816524B (zh)	2012-06-27

Publication	Publication Date	Title
DK2009000T3 (da)	2011-09-05	Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
BRPI0418052A2 (pt)	2017-04-18	derivados de ciclohexano espiro-cíclicos com afinidade para o receptor orl1
ATE451364T1 (de)	2009-12-15	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
CL2011000044A1 (es)	2011-06-17	Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
IS8483A (is)	2006-05-26	Heterósýklísk virk efni gegn mígreni
BRPI0617241A2 (pt)	2016-11-08	composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo
EP1690550A4 (en)	2009-07-15	THERAPEUTIC AGENT AGAINST MESOTHELIOM
ATE384697T1 (de)	2008-02-15	2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
DE602004012891D1 (de)	2008-05-15	Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
IL182047A0 (en)	2007-07-24	Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents
ZA200604791B (en)	2008-07-30	Hydronopol derivatives as agonists on human ORL1 receptors
MA28495B1 (fr)	2007-03-01	Derives d'oxadiazolone agonistes de ppar-delta
DE60319626D1 (de)	2008-04-24	Feuchtmittelversorgungsapparat vom Spraytyp
HRP20150320T1 (xx)	2015-07-03	Formulacije i metode za lijeäśenje amiloidoze
EP1951709A4 (en)	2010-11-10	IMIDAZOLIDINONE COMPOUNDS AS A BETA SECRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
SE0302794D0 (sv)	2003-10-24	Novel microparticles for ultrasound contrast imaging and drug delivery
EP1876175A4 (en)	2012-06-27	THERAPEUTICS FOR CORNEAL DISEASE
ITVR20050060A1 (it)	2006-11-17	Macchina per la pulitura di scale mobili e simili, particolarmente per eseguire la pulizia dell'alzata degli scalini.
DE50300597D1 (de)	2005-07-07	Fanghakeneinrichtung für eine Fronthaube eines Kraftfahrzeugs
UA13322S (uk)	2006-12-15	Пальто жіноче хутрове комбіноване «вишневий йогурт». модель мв
UA11825S (uk)	2006-03-15	Куртка жіноча хутрова «моніка». модель 20-мв.
ITMI20040411A1 (it)	2004-06-04	Macchina perfezionata per l'inscatolamento di pesce carne e simili
ITCT20050007A1 (it)	2006-10-21	Metodo per la riduzione dell'impatto ambientale e del costo di abbattimento degli agenti chimici dannosi all'ambiente
GB0524046D0 (en)	2006-01-04	Improvement in oral hygiene agents
ITFR20040016A1 (it)	2005-01-13	Macchina per prove di fatica su cateteri ad uso medicale